Articles

Emerging markets give Lilly hope in patent crunch

In a kind of alternate drug universe, sales of Eli Lilly and Co.’s ghosts of blockbusters past are soaring in China—prompting the drugmaker to pour money into emerging markets in an attempt to prop up revenue.

Read More

Recent successes don’t change Lilly’s outlook

Eli Lilly and Co. can be credited with using acquisitions to unclog its product pipeline. It launched two drugs in the past 18 months, won market approval for a third and will likely get nods for two more drugs this year. Trouble is, they all have paltry sales prospects.

Read More

Duke Realty reports strong year-end results

Duke Realty Corp. reported a fourth-quarter profit almost 70 percent above last year's figure as it closed out its best leasing year since 2007 and finished with its highest annual portfolio occupancy rate since 2004.

Read More

WellPoint profit better than analyst estimates

Excluding special charges, WellPoint’s profit fell 2 percent to $524.7 million in the fourth quarter from $536 million in the fourth quarter of 2009. But earnings per share improved thanks to stock buybacks.

Read More